Bialasiewicz A A, Ma J X, Richard G
University Eye Hospital Eppendorf, Hamburg, Germany.
Br J Ophthalmol. 1999 Sep;83(9):1069-73. doi: 10.1136/bjo.83.9.1069.
To detect specific tumour infiltrating T cells (TIL) carrying antigen specific MHC-I restricted receptor genes on necrotising and non-necrotising malignant melanomas and to correlate the findings with clinical data.
alpha/beta- and gamma/delta- TIL were determined by immunohistochemical staining in melanomas of patients with known follow up of more than 10 years. An antigen retrieval method was used to determine variable genes delta1 and gamma1 on TCR(+) cells by an anti-TCR Vdelta1 and anti-CrgammaM1, and of Valpha and Vbeta TCR(+) by an anti-pan-TCR(+) alpha/beta antibody.
Intratumoral TIL were present in 86 of 113 (76.1%) necrotising melanomas (NMM) v 21 of 100 (21%) in non-necrotising melanomas (MM); of these, Valpha/beta- TCR(+) cells were present in 52 of 74 (70.3%) TIL harbouring NMM v four of 21 (19%) MM; Vgamma1 in 29 of 74 (39.2%) NMM v two of 21 (10%) MM; and Vdelta1 in 39 of 74 (52.7%) NMM v three of 21 (14%) MM. Extratumoral lymphocytic infiltration was seen in 86 (76.1%) NMM including Valpha/beta TCR(+) cells in 10 (11.6%) cases, v five (5%) MM cases with no Valpha/beta TCR(+) cells detected. Vgamma1 and Vdelta1 TCR(+) cells were not found in extratumoral infiltrates.
In NMM, the median survival was 69.3 (range 6-237) months, 19 of 74 patients (25.7%) survived 5 years, and mortality was associated with advanced stage (p<0.001), patient age (p<0.023), and extent of necrosis (p<0.048). Survival was increased with evidence of Vgamma1 and Vdelta1 TCR(+) cells (p<0.026).
检测携带抗原特异性MHC-I限制性受体基因的特异性肿瘤浸润T细胞(TIL),这些T细胞存在于坏死性和非坏死性恶性黑色素瘤中,并将研究结果与临床数据相关联。
对随访时间超过10年的患者的黑色素瘤,通过免疫组织化学染色来确定α/β-和γ/δ-TIL。采用抗原修复方法,通过抗TCR Vδ1和抗CrγM1来确定TCR(+)细胞上的可变基因δ1和γ1,通过抗泛TCR(+)α/β抗体来确定Vα和Vβ TCR(+)。
113例坏死性黑色素瘤(NMM)中有86例(76.1%)存在瘤内TIL,而100例非坏死性黑色素瘤(MM)中有21例(21%)存在瘤内TIL;其中,74例携带NMM的TIL中有52例(70.